FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Science Venture Capital Monitor – 01/2020”.
The Monitor is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying venture capital financing trends in the European life science industry.
Key insights for January 2020 are:
- With EUR 349m funding volume on par with January 2019
- BioTech/Pharma with 56% of the funding volume well ahead
- High-Tech Gründerfonds and Boehringer Ingelheim Venture among most active investors
- Swiss, French and UK companies receive almost 75% of the investments
To access the full report, please click here.